| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2026-02-10 |
| タイトル |
|
|
タイトル |
Prognostic impact of systolic blood pressure and antithrombotic strategy in patients with atrial fibrillation and stable coronary artery disease: a post-hoc analysis of the AFIRE trial |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Atrial fibrillation |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Coronary artery disease |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Monotherapy |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Systolic blood pressure |
| 資源タイプ |
|
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
| 著者 |
Yamanaka, Shinichi
Noda, Takashi
Nochioka, Kotaro
Higuma, Takumi
海北, 幸一
WEKO
34072
e-Rad_Researcher
30346978
| ja |
海北, 幸一
宮崎大学
|
| ja-Kana |
カイキタ, コウイチ
|
| en |
Kaikita, Koichi
University of Miyazaki
|
Search repository
Akao, Masaharu
| en |
Akao, Masaharu（Personal）
National Hospital Organization Kyoto Medical Center
|
Search repository
Ako, Junya
Matoba, Tetsuya
Nakamura, Masato
Miyauchi, Katsumi
| en |
Miyauchi, Katsumi（Personal）
Juntendo Tokyo Koto Geriatric Medical Center
|
Search repository
Hagiwara, Nobuhisa
Kimura, Kazuo
Matsui, Kunihiko
Ogawa, Hisao
Yasuda, Satoshi
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Backgrounds: The AFIRE (Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease) trial demonstrated that rivaroxaban monotherapy was non-inferior in efficacy and superior in safety compared to rivaroxaban plus single antiplatelet therapy in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD). This study examined whether systolic blood pressure (SBP) affects clinical outcomes and modifies the impact of antithrombotic therapy. Methods: In this post hoc analysis, participants were stratified based on median SBP at baseline: >126 mmHg (High SBP group, n = 1042) and ≤126 mmHg (Low SBP group, n = 1093). The primary efficacy endpoint was a composite of cardiovascular events and all-cause death. The primary safety endpoint was major bleeding. Results: The mean SBP was 139 mmHg and 114 mmHg in the High and Low SBP groups, respectively. In the propensity score-matched cohort (n = 1684), the Low SBP group had a significantly higher incidence of the primary efficacy endpoint (hazard ratio [HR], 1.38; 95% confidence interval [CI], 1.01–1.88; p = 0.039), while the primary safety endpoint was comparable between groups. In the Low SBP group, rivaroxaban monotherapy was associated with lower risks of both the primary efficacy (HR, 0.60; 95% CI, 0.41–0.86; p = 0.006) and safety endpoints (HR, 0.40; 95% CI, 0.22–0.74; p = 0.003) compared with combination therapy, whereas no significant differences were observed in the High SBP group. Conclusions: Lower SBP was associated with increased risk of cardiovascular events and all-cause death. Rivaroxaban monotherapy demonstrated more favorable efficacy and safety outcomes particularly patients with lower SBP. |
|
言語 |
en |
| 書誌情報 |
en : Hypertension research : official journal of the Japanese Society of Hypertension
発行日 2026-01-05
|
| 出版者 |
|
|
出版者 |
Springer Science and Business Media LLC |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
13484214 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1038/s41440-025-02449-9 |
| 権利 |
|
|
権利情報 |
© The Author(s) 2025. |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
Fulltext (1.9 MB)
.png)
